Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MTOR | P42345 | 7/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24378616 | 0.80 | CYP1A2 (0.42) | CYP1A2CYP2D6MAPTRAF1BRAF | |
| SCHEMBL22727799 | 0.78 | POLB (0.43) | CYP1A2CYP2D6MAPTKMT2APIK3CA | |
| SCHEMBL24378544 | 0.76 | KDM4E (0.42) | CYP1A2CYP2D6MAPTRAF1BRAF | |
| SCHEMBL24378565 | 0.75 | MAPT (0.40) | CYP1A2CYP2D6MAPTRAF1BRAF | |
| SCHEMBL27009158 | 0.74 | PIK3CA (0.49) | MAPTKMT2APIK3CAKDM4ERAB9A | |
| SCHEMBL1497393 | 0.72 | CYP1A2 (0.56) | CYP1A2CYP2D6MAPTRAF1BRAF | |
| SCHEMBL27009156 | 0.69 | KDM4E (0.56) | CYP1A2CYP2D6MAPTKMT2AKDM4E | |
| SCHEMBL24378575 | 0.69 | KDM4E (0.44) | CYP1A2CYP2D6MAPTRAF1BRAF | |
| SCHEMBL24378567 | 0.69 | MAPT (0.42) | CYP1A2CYP2D6MAPTRAF1BRAF | |
| SCHEMBL23649017 | 0.68 | MAPT (0.44) | CYP1A2CYP2D6MAPTKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2024-01-18 | — | — | US | disclosed |
| WO-2022086993-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC (US) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | PIKFYVE, PIK3CD, PIK3R5 | CYP1A2 4703/4885CYP2D6 4685/4885MAPT 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.